The FDA and European Medicines Agency have given Pharnext SAS an orphan drug designation to its PXT-3003 for the treatment of Charcot-Marie-Tooth disease type 1A. PXT-3003 is an oral fixed low-dose combination of baclofen, naltrexone and sorbital. The orphan drug…
Day: June 24, 2014
Charcot-Marie-Tooth disease treatment receives orphan drug designation
The FDA and European Medicines Agency have given Pharnext SAS an orphan drug designation to its PXT-3003 for the treatment of Charcot-Marie-Tooth disease type 1A. PXT-3003 is an oral fixed low-dose combination of baclofen, naltrexone and sorbital. The orphan drug…
3-D printing design studio closes seed round funding
UNYQ, an interactive 3-D printing studio that allows amputees to design customizable protective prosthetic covers, recently closed seed round funding at more than $1 million. “The seed funding will enable us to invest in state-of-the-art 3-D printers and related technologies,”…